Lysosomal polygenic risk score in Parkinson's disease across populations.

Abstract

BackgroundLysosomal dysfunction has been implicated in Parkinsons disease (PD) pathogenesis. However, lysosomal polygenic risk scores (lyso-PRS) have not been evaluated extensively in PD across populations.

Objectives(1) Evaluation of lyso-PRS (lyso-PRS) performance for PD risk across populations; (2) Comparison of lyso-PRS across idiopathic PD (iPD), GBA1-PD, non-manifesting GBA1 carriers (NMC), and healthy controls (HC) in the European population. (3) Assessment of the lyso-PRS association with clinical outcomes in the PD patients of European population.

MethodsWe analyzed Neurobooster array data from the Global Parkinsons Genetics Program (GP2) dataset, including 32,054 iPD cases and 18,188 healthy controls across ten ancestries.

Results(1) lyso-PRS performed best in Europeans (European-GP2 test cohort: AUC = 0.602, p = 2.02e-172; European-TUEPAC validation cohort: AUC = 0.632, p = 5.34e-20) and worse in other populations (AUC: 0.51-0.59, p<0.05). (2) In the European population, the lyso-PRS distinguished GBA1-PD from HC (AUC = 0.621, p = 7.83e-71) and from NMC (AUC = 0.621, p = 1.05e-18). (3) In the European-GP2 cohort, higher lyso-PRS was significantly associated with earlier age at onset ({beta}=-0.21, p=0.022) and higher Unified Parkinsons Disease Rating Scale (UPDRS) scores ({beta}=0.32-1.13, all p < 0.05).

Conclusionslyso-PRS was associated with iPD and GBA1-PD status, with the strongest predictive performance in the European population, underscoring the need to improve accuracy in other ancestries. In the European population, the lyso-PRS showed associations with clinical features; however, not all findings were replicated in the validation cohort, highlighting the need for further investigation in large and diverse cohorts.

The landscape of polygenic score prediction accuracy and transportability across the phenome in ancestrally diverse populations
M. Lin, C. H. Arehart, S. N. K. Walker +14
medRxiv8 Oct 2026PreprintCC BY-NC-NDFull textHuman geneticsmedRxiv
Machine learning image analysis predicts Parkinson disease genotype and mitochondrial lysosomal abnormalities in iPS neurons.
Yan Li, Maximilian Powell, Jessica Chedid +17
NPJ Parkinson's disease1 Aug 2026Peer-reviewedCC BYFull textNeurologyEurope PMCDOAJ
A rare TMEM175 mutation drives Parkinson's disease pathology by disrupting proton gating and lysosomal acidification.
Xiaotong Yang, Ping Li, Man Lv +17
The Journal of clinical investigation2 Nov 2026Peer-reviewedCC BYFull textNeurologyEurope PMCPMC
Polygenic overlap of physical activity with schizophrenia and Parkinson's disease
K. van der Walt, A. Shadrin, M. Tesfaye +4
medRxiv23 Jun 2026PreprintCC BY-NDFull textPsychiatry & mental healthmedRxiv
Considerations for therapeutic targets for clinical trials in biomarker-characterized prodromal Parkinson's disease populations
RB Schneider, G Skibinski, B Fiske +3
Journal of Parkinson’s Disease4 Nov 2026Peer-reviewedCC BYFull textNeurologyDOAJ

Cite

BibTeX RIS

BibTeX

@misc{sun2026lysosomal,
  title = {{Lysosomal polygenic risk score in Parkinson's disease across populations.}},
  author = {W. Sun and K. Brockmann and I. Wurster and R. Kemmner and B. Roeben and R. Skaiene and S. Lerche and C. Schulte and T. Gasser and M. Tan and the Global Parkinson's Genetic Program (GP2)},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.14.26362981},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Lysosomal polygenic risk score in Parkinson's disease across populations.
AU  - W. Sun
AU  - K. Brockmann
AU  - I. Wurster
AU  - R. Kemmner
AU  - B. Roeben
AU  - R. Skaiene
AU  - S. Lerche
AU  - C. Schulte
AU  - T. Gasser
AU  - M. Tan
AU  - the Global Parkinson's Genetic Program (GP2)
PY  - 2026
DA  - 2026/09/14
PB  - medRxiv
DO  - 10.64898/2026.09.14.26362981
UR  - https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1
AB  - BackgroundLysosomal dysfunction has been implicated in Parkinsons disease (PD) pathogenesis. However, lysosomal polygenic risk scores (lyso-PRS) have not been evaluated extensively in PD across populations.  Objectives(1) Evaluation of lyso-PRS (lyso-PRS) performance for PD risk across populations; (2) Comparison of lyso-PRS across idiopathic PD (iPD), GBA1-PD, non-manifesting GBA1 carriers (NMC), and healthy controls (HC) in the European population. (3) Assessment of the lyso-PRS association with clinical outcomes in the PD patients of European population.  MethodsWe analyzed Neurobooster array data from the Global Parkinsons Genetics Program (GP2) dataset, including 32,054 iPD cases and 18,188 healthy controls across ten ancestries.  Results(1) lyso-PRS performed best in Europeans (European-GP2 test cohort: AUC = 0.602, p = 2.02e-172; European-TUEPAC validation cohort: AUC = 0.632, p = 5.34e-20) and worse in other populations (AUC: 0.51-0.59, p<0.05). (2) In the European population, the lyso-PRS distinguished GBA1-PD from HC (AUC = 0.621, p = 7.83e-71) and from NMC (AUC = 0.621, p = 1.05e-18). (3) In the European-GP2 cohort, higher lyso-PRS was significantly associated with earlier age at onset ({beta}=-0.21, p=0.022) and higher Unified Parkinsons Disease Rating Scale (UPDRS) scores ({beta}=0.32-1.13, all p < 0.05).  Conclusionslyso-PRS was associated with iPD and GBA1-PD status, with the strongest predictive performance in the European population, underscoring the need to improve accuracy in other ancestries. In the European population, the lyso-PRS showed associations with clinical features; however, not all findings were replicated in the validation cohort, highlighting the need for further investigation in large and diverse cohorts.
ER  -

Abstract

Related

Cite